Evaluating Prenatal Exome Sequencing Study

Genetic Diseases, Inborn Clinical Trial

— EPES  

Official title:

Evaluating Prenatal Exome Sequencing Study

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05290701
• Other study ID #: NL77927.058.21
• Status: Enrolling by invitation
• Start date: February 21, 2022
• Est. completion date: April 1, 2025

Study information

• Verified date: October 2023
• Source: Leiden University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study evaluates the impact of the various outcomes of pES (definitive diagnosis, probable diagnosis and IF) on clinical decision making and on parental psychological wellbeing, compared between different analysis strategies to investigate the clinical utility, defined as the balance between potential harms and benefits.

Description:

Foetal anomalies as detected on prenatal ultrasound are present in 2-3% of pregnancies. The diagnosis of a genetic syndrome as the underlying cause often has significant consequences for the prognosis and therefore also a significant impact on parental reproductive decision making. In addition to chromosomal testing, prenatal exome sequencing (pES) is increasingly being offered. Although prenatal diagnostic rates are promising, no studies report on the actual implementation of pES in routine care and thus several important knowledge gaps remain regarding clinical utility (the balance between potential harms and benefits) and the preferred analysis strategy (broad versus targeted analysis). A broad analysis has a possible higher diagnostic yield, but it is unknown whether the increased chance of finding an uncertain diagnosis and Incidental Findings outweighs this benefit when it comes to clinical decision making and parental psychological wellbeing. The central aim of this study is to address the knowledge gaps raised above, and increase clinical utility by using the obtained data to improve analysis strategies and to potentially identify new genes.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 1000
• Est. completion date: April 1, 2025
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least one fetal anomaly detected in the current pregnancy, irrespective of gestational age;
• Pregnancy ongoing;
• Mother at least 18 years old and providing consent for pES;
• If father is available: father at least 18 years old and providing consent for pES. Exclusion Criteria: There are no exclusion criteria.

Related Conditions & MeSH terms

• Congenital Abnormalities
• Congenital Anomalies
• Genetic Diseases, Inborn
• Mendelian Disorders

Locations

Country	Name	City	State
Netherlands	Leiden University Medical Centre	Leiden	Zuid-Holland

Sponsors (1)

Lead Sponsor	Collaborator
Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of identified new disease genes		2 years
Primary	Percentage of definitive diagnoses, probable diagnoses and incidental findings (IF)		2 years
Secondary	Patients perspectives on probable diagnoses and incidental findings including psychological wellbeing as measured by questionnaires.	We will use validated scales such as the State Trait Anxiety Inventory-6, the Decisional Conflict Scale, the Decisional Regret Scale, the Intolerance of Uncertainty Scale, the Impact of Event Scale and the Pre- and Postnatal Bonding Scale.	2 years
Secondary	Clinical impact of prenatal exome sequencing (pES)	Clinical impact will be defined as medical or surgical in utero intervention, pregnancy termination, location and mode of delivery, decisions on comfort care and neonatal policy influenced by the results of pES.	2 years
Secondary	Impact of different analysis strategies on the distribution of the various outcomes of pES (definitive diagnosis, probable diagnosis and incidental findings)	pES data of all included pregnancies will be retrieved and re-analyzed to minimize differences in variant interpretation and to determine the impact of different analysis strategies on the percentages of various outcomes of pES (definitive diagnoses, probable diagnoses and incidental findings). Different analysis strategies will be employed: analysis of an HPO-based gene panel, analysis of an established gene panel of genes causing multiple congenital anomalies and/or intellectual disability, and analysis of all genes.	2 years